Topics

Human medicines European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate), clopidogrel, Acute Coronary Syndrome,Peripheral Vascular Diseases,Myocardial Infarction,Stroke, Date of authorisation: 27/07/2009, Revision: 13, Status: Author

07:23 EDT 4 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate), clopidogrel, Acute Coronary Syndrome,Peripheral Vascular Diseases,Myocardial Infarction,Stroke, Date of authorisation: 27/07/2009, Revision: 13, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate), clopidogrel, Acute Coronary Syndrome,Peripheral Vascular Diseases,Myocardial Infarction,Stroke, Date of authorisation: 27/07/2009, Revision: 13, Status: Author

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Clopidogrel Teva (hydrogen sulphate), clopidogrel, Acute Coronary Syndrome,Peripheral Vascular Diseases,Myocardial Infarction,Stroke, Date of authorisation: 27/07/2009, Revision: 13, Status: Author"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...